Navigation Links
Innovive Pharmaceuticals Announces Additional Data Presentations at,American Association for Cancer Research Annual Meeting

NEW YORK--(BUSINESS WIRE)--Apr 12, 2007 - INNOVIVE Pharmaceuticals, Inc. (OTCBB:IVPH) today announced that data from preclinical studies of INNO-406, a potent oral dual Bcr-Abl and Lyn-kinase inhibitor for Gleevec-resistant or treatment-intolerant chronic myelogenous leukemia, will be presented at the American Association for Cancer Research Annual Meeting. The meeting takes place April 14-18, 2007 at the Los Angeles Convention Center in Los Angeles, California.

Information related to the presentations is as follows: -0-

Presentation Title:    "The dual ABL/SRC inhibitors dasatinib,

                       SKI-606, and INNO-406 are potent inhibitors of

                       T cell acute lymphoblastic leukemia cell lines

                       expressing the NUP214-ABL1 fusion kinase"


Abstract Number:       1825


Session:               Poster Section 7, Clinical Research 8, Poster

                       Board #11


Session Date and Time: Monday, April 16, 2007, 8:00 a.m. - 12:00 p.m.


Location:              Exhibit Hall, Los Angeles Convention Center





Presentation Title:    "Cell death and autophagy induced by INNO-406,

                       a novel Bcr-Abl inhibitor, in Philadelphia

                       leukemias"


Abstract Number:       2768


Session:               Poster Section 10, Cellular and Molecular

                       Biology 31, Poster Board #17


Session Date and Time: Monday, April 16, 2007, 1:00 p.m. - 5:00 p.m.


Location:              Exhibit Hall, Los Angeles Convention Center

-0-
Presentation Title:    "Overcoming imatinib resistance using Src

                       inhibitor CGP76030, Abl inhibitor nilotinib,

                       and Abl/Lyn inhibitor INNO-406 in newly

                       established K562 variants with bcr-abl gene

                       amplification"


Abstract Number:       3246


Session:               Poster Section 29, Experimental and Molecular

                     
  Therapeutics 26, Poster Board #8


Session Date and Time: Monday, April 16, 2007, 1:00 p.m. - 5:00 p.m.


Location:              Exhibit Hall, Los Angeles Convention Center

About INNO-406

INNO-406 (formerly known as NS-187) is an orally bioavailable, rationally designed, dual Bcr-Abl and Lyn-kinase inhibitor currently in Phase I clinical studies. According to a study published in the journal Blood (Dec. 1, 2005), INNO-406 is 25 to 55 times more potent than imatinib in vitro, and at least 10 times as effective as imatinib mesylate in suppressing the growth of Bcr-Abl bearing tumors. INNO-406 has demonstrated activity in 12 of 13 imatinib-resistant cell lines. In addition to its Bcr-Abl inhibitory properties, INNO-406 inhibits Lyn kinase. Upregulation of Lyn kinase activity is a well recognized cause of imatinib resistance. Lyn kinase activation has also been documented in a variety of solid tumors, including prostate cancer.

About INNOVIVE Pharmaceuticals

INNOVIVE Pharmaceuticals, Inc. acquires, develops and commercializes novel therapeutics addressing significant unmet medical needs in the fields of oncology and hematology. The company has four drug programs in clinical development: INNO-406, Tamibarotene, INNO-206, and INNO-305, for the treatment of chronic myelogenous leukemia, acute promyelocytic leukemia, small cell lung cancer, and acute myelogenous leukemia, respectively. For additional information visit www.innovivepharma.com.

Contact

INNOVIVE Pharmaceuticals
Steve Kelly
President and CEO
212-716-1820
or
Porter Novelli Life Sciences
Rachel Lipsitz
Media & Investor Relations
619-849-5378


'"/>




Related medicine technology :

1. Innovive Pharmaceuticals to Present Interim Data from Phase I Study of INNO-406 at the American Society of Clinical Oncology Annual Meeting
2. Innovive Pharmaceuticals Announces Preclinical Data from INNO-206 Oncology Program
3. Innovive Pharmaceuticals Announces Data from Oncology Drug Programs to be Presented at American Association for Cancer Research Annual Meeting
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... PUNE, India , April 28, 2016 /PRNewswire/ ... - Pipeline Review, H1 2016" is a report ... pipeline and helps strengthen R&D pipelines by identifying ... best-in-class products. Company Profiles discussed in ... Menarini Industrie Farmaceutiche Riunite Srl, AbbVie Inc., Abiogen ...
(Date:4/27/2016)... , Schweiz, April 27, 2016 /PRNewswire/ ... des Sachs CEO Forums in Zürich gab ... ihres führenden Wirkstoffkandidaten STR001 zur Erhaltung des ... eingesetzt wurde, bekannt. Für die umfassende Phase-II-Doppelblindstudie ... und Frankreich angeworben. STR001 wird während der ...
(Date:4/27/2016)...   , Total Sales Grow ... Clinical sales grow 16% year-over-year  , ... MKEAY) inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy ... ended March 31, 2016 and provided an update on ... First Quarter 2016 Revenue Results by Category  ...
Breaking Medicine Technology:
(Date:4/28/2016)... ... April 28, 2016 , ... Amada Senior Care, premier provider of non-medical in-home ... – its San Antonio West location. Prior to entering the senior care industry, Amada ... opening of Amada San Antonio West will take place on Friday, April 29th. ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... the development of miniature microphones and headsets announced today that the US Patent ... of integrating in-earphones into a structure. This innovative design creates a lightweight and ...
(Date:4/28/2016)... ... , ... Metabolic Nutrition today announced the upcoming launch of its ... Get Fit and Sports Expo in Orlando, Florida. Attended by pro athletes, ... 29-30, was selected as the perfect event to introduce the highly anticipated GlycoLoad. ...
(Date:4/28/2016)... ... April 28, 2016 , ... The Aging in ... has established an ICD-10-CM code for sarcopenia, giving it recognition for separate reporting and ... effective October 1, 2016. , Sarcopenia is defined as a combination of low muscle ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... to those affected by a health insurance co-operative bankruptcy to receive their ... individuals can receive over 1,500 FDA-approved prescription medications from over 180 American ...
Breaking Medicine News(10 mins):